These studies supports durvalumab as a viable first-line option for metastatic NSCLC, particularly in PD-L1–low or negative patients, but its incremental benefit and optimal patient selection require further clarification in future comparative studies. The gene discussed is CD274; the disease is non-small cell lung carcinoma.